Open AccessMiR-455-5p Suppresses the Progression of Prostate Cancer by Targeting CCR5
Author(s) -
Qianwei Xing,
Huyang Xie,
Bingye Zhu,
Zhiwei Sun,
Yeqing Huang
Publication year - 2019
Publication title -
biomed research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 126
eISSN - 2314-6141
pISSN - 2314-6133
DOI - 10.1155/2019/6394784
Subject(s) - prostate cancer , cancer research , carcinogenesis , apoptosis , suppressor , tumor progression , cell growth , cancer , microrna , tramp , biomarker , chemokine , biology , medicine , receptor , gene , genetics , biochemistry
Accumulated evidence indicates that miR-455-5p functions as tumor suppressor in the progression of various cancers. However, the mechanism through which miR-455-5p influences the tumorigenesis of human prostate cancer (PCa) remains undetermined. In this study, reanalysis of data obtained from the Memorial Sloan Kettering Cancer Center showed that miR-455-5p can be used as biomarker for PCa diagnosis and predictor of poor prognosis. Functional assays indicated that miR-455-5p overexpression could suppress cellular proliferation, inhibit tumor growth, and trigger apoptosis by activating and cleaving caspase 3. We experimentally verified that miR-455-5p negatively regulated the C–C motif chemokine receptor 5 (CCR5). Overall, our data demonstrate that miR-455-5p suppressed PCa cellular proliferation and induced cell apoptosis by downregulating CCR5. Thus, miR-455-5p may be considered a new therapeutic strategy for PCa.